Learn more about AbbVie's response to COVID-19

Moderate to Severe

Juvenile Idiopathic Arthritis

Non-Infectious

Intermediate, Posterior and Panuveitis

Active

Psoriatic Arthritis

Moderate to Severe

Hidradenitis Suppurativa

Refractory, Moderate to Severe

Atopic Dermatitis

Gastroenterology

Moderate to Severe

Crohn's Disease

Moderate to Severe

Pediatric Crohn's Disease

Moderate to Severe

Ulcerative Colitis

Moderate to Severe

Pediatric Ulcerative Colitis

Ophthalmology

Non-Infectious

Intermediate, Posterior and Panuveitis

For moderate to severe rheumatoid arthritis (RA) in adult TNFi-IR patients1
For active psoriatic arthritis (PsA) in adult TNFi-IR patients1

Abbvie's
commitment to
exceptional
access and patient
support

Get started with the Enrollment & Prescription Form

Get started with the Enrollment & Prescription Form

Confidence in access

ACCESS AVAILABLE THROUGH INSURANCE OR
RINVOQ COMPLETE

greater than 9 out of 10

Commercial patients
have access to RINVOQ PsA2


Encourage your patients to enroll in

Encourage your patients to enroll in

Access is available as of December 2021 and through commercial insurance, or through RINVOQ Complete if coverage is denied.

Affordability: Eligible commercially insured patients may pay as little as $5 per month.

Access: No charge for eligible patients experiencing initial insurance delay or denial for
up to 24 months*,†

Exceptional 1:1 patient experience when your patients enroll in RINVOQ Complete

GET STARTED WITH THE ENROLLMENT & PRESCRIPTION FORM

*Available only to patients with commercial insurance who meet eligibility criteria. See enrollment form for full Terms and Conditions.

Commercial insurance coverage varies by type and plan. The Complete Program is not available to patients receiving prescription reimbursement under any federal, state, or government funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government funded healthcare program, patient will no longer be eligible to participate in program. Available to patients between the ages of 18-63 with commercial prescription insurance coverage who meet eligibility criteria. Eligibility: Patients must be diagnosed with active psoriatic arthritis, have a valid prescription for RINVOQ® and participate in a commercial insurance plan that has denied or not yet made a formulary decision for RINVOQ. Once the patient’s insurance plan has made a formulary decision and established a process for reviewing coverage requests for RINVOQ, continued eligibility for the program requires the submission of a Prior Authorization prior to the next scheduled dose and appeal of the coverage denial within 180 days. Program provides RINVOQ at no charge to patients for up to 2 years or until they receive insurance coverage approval, whichever occurs earlier. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage.

TIM=targeted immunomodulator; TNFi=tumor necrosis factor inhibitor

Two products.
One exceptional patient experience.

RINVOQ™ COMPLETE
HUMIRA® COMPLETE

Nurse
Ambassadors*

Empower patients

Our Nurse Ambassadors are the heart of RINVOQ Complete and HUMIRA Complete

Nurse Ambassadors provide 1:1 support to help patients start and stay on track with their prescribed treatment plan, including:

  • Committed to answering questions throughout the experience to help limit treatment disruptions.
  • Answer patients’ insurance questions, help them identify ways to save on prescription costs and connect them with additional insurance expertise.

Insurance
SPECIALISTS

Insurance support when needed

Insurance Specialists:

  • Resource with expertise on Medicare and commercial plans at a national, local, and program level so that they can educate on potential options to consider based on each patient’s unique financial situation.
  • Can educate on payer prior authorization and appeal processes so you can determine the best access option for each patient’s unique situation.

ACCESS & SAVINGS

Help with access & treatment affordability

COMPLETE can help your commercially insured patients save: 

  • With the Complete Savings Card, your eligible commercially insured patients may pay as little as $5 per month.
  • Rinvoq Complete may help eligible commercially insured patients experiencing initial coverage delays or denials access their prescribed therapy at no charge while coverage is established. Eligibility criteria apply.
  • Please see Terms and Conditions found in Footnotes and Definitions.

THE COMPLETE APP

Help patients
track treatment

The RINVOQ Complete and HUMIRA Complete apps are designed to help patients stay on track with their treatment plan by helping them:

  • Access additional resources, including savings card for those who are eligible.
  • Set up medication reminders.
  • Log symptoms.
  • Log medication lot number and medication expiration date.
Complete App Store Download
Complete App Google Play Download

ADDITIONAL RESOURCES

Ongoing Education:

  • RINVOQ Complete builds on the HUMIRA Complete program and continues to provide helpful information and resources through life changes that can affect insurance coverage, including open enrollment and job status changes.

RINVOQ Specialty Pharmacy Resources:

  • RINVOQ is broadly available through open distribution, and prescriptions may be sent to the specialty pharmacy of the patient's choosing.
  • In addition to open distribution, contracted specialty pharmacies have the capability to:
    • Help facilitate enrollment into RINVOQ Complete
    • Inform patients and your staff if the RINVOQ prescription must be transferred to another pharmacy mandated by the patient's insurance
    • Provide education on insurance process requirements

Empowering Patients
Nurse Ambassadors, In Their Own Words

Have questions or need support over the phone?

Call 1-877-COMPLETE
(1-800-274-6867)

*Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing healthcare professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.

RINVOQ Complete: Terms and Conditions apply. This benefit covers RINVOQ® (upadacitinib) alone or for RINVOQ plus one of the following medications: methotrexate, leflunomide (Arava®), or hydroxychloroquine (Plaquenil®). Eligibility: Available to patients with commercial prescription insurance coverage for RINVOQ who meet eligibility criteria. Co‑pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government‑funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government‑funded healthcare program, patient will no longer be able to use the RINVOQ Complete Savings Card and patient must call RINVOQ Complete at 1.800.2RINVOQ to stop participation. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from the RINVOQ Complete program from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. Patients who are members of insurance plans that claim to reduce or eliminate their patients' out-of-pocket co-pay, co‑insurance, or deductible obligations for certain prescription drugs based upon the availability of, or patient's enrollment in, manufacturer sponsored co‑pay assistance for such drugs (often termed "maximizer" programs) will have an annual maximum program benefit of $6,000.00 per calendar year. This assistance offer is not health insurance. To learn about AbbVie’s privacy practices and your privacy choices, visit www.abbvie.com/privacy.html

HUMIRA Complete: Terms and Conditions apply. This benefit covers HUMIRA® (adalimumab) alone or, for rheumatology patients, HUMIRA plus one of the following medications: methotrexate, leflunomide (Arava®), or hydroxychloroquine (Plaquenil®). Eligibility: Available to patients with commercial prescription insurance coverage for HUMIRA who meet eligibility criteria. Co‑pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government‑funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government‑funded healthcare program, patient will no longer be able to use the HUMIRA Complete Savings card and patient must call HUMIRA Complete at 1-800-4HUMIRA to stop participation. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from the HUMIRA Complete Program from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. Patients who are members of insurance plans that claim to reduce or eliminate their patients' out-of-pocket co-pay, co-insurance, or deductible obligations for certain prescription drugs based upon the availability of, or patient's enrollment in, manufacturer sponsored co-pay assistance for such drugs (often termed "maximizer" programs) will have an annual maximum program benefit of $6,000.00 per calendar year. This assistance offer is not health insurance. To learn about AbbVie’s privacy practices and your privacy choices, visit www.abbvie.com/privacy.html

Arava and Plaquenil are registered trademarks of their respective owners.

Program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be eligible to participate in program. Available to patients between the ages of 18-63 with commercial prescription insurance coverage who meet eligibility criteria. Eligibility: Patients must be diagnosed with active psoriatic arthritis, have a valid prescription for RINVOQ and participate in a commercial insurance plan that has denied or not yet made a formulary decision for RINVOQ. Once the patient’s insurance plan has made a formulary decision and established a process for reviewing coverage requests for RINVOQ, continued eligibility for the program requires the submission of a Prior Authorization prior to the next scheduled dose and appeal of the coverage denial within 180 days. Program provides RINVOQ at no charge to patients for up to 2 years or until they receive insurance coverage approval, whichever occurs earlier. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage.

How to Enroll Patients in the
Complete Program

Help patients get the support they need to start and stay
on track with their prescribed treatment

To enroll a patient in RINVOQ Complete:

1

Fill out the form with your patient
This form enrolls your patient and can be used to initiate a prescription with your patient’s preferred specialty pharmacy.

2

Fill out the patient support prescription in Section 6
This may help your commercially insured patients get access to RINVOQ if they experience a delay or denial in their insurance coverage.*

3

Fax the form to 1-6‍7‍8-7‍2‍7-0‍6‍9‍0 and to the patient's chosen specialty pharmacy
You will receive a call from an Insurance Specialist to discuss next steps. In addition, fax the form to your patient’s specialty pharmacy if using the Pharmacy Prescription in Section 9.

4

Inform your patient that they have been enrolled
Let your patient know that they will be receiving a call from their Nurse Ambassador.†

*Program is not available to patients receiving prescription reimbursement under any federal, state, or government‑funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government‑funded healthcare program, patient will no longer be eligible to participate in program. Available to patients between the ages of 18-63 with commercial prescription insurance coverage who meet eligibility criteria. Eligibility: Patients must be diagnosed with active psoriatic arthritis, have a valid prescription for RINVOQ and participate in a commercial insurance plan that has denied or not yet made a formulary decision for RINVOQ. Once the patient’s insurance plan has made a formulary decision and established a process for reviewing coverage requests for RINVOQ, continued eligibility for the program requires the submission of a Prior Authorization prior to the next scheduled dose and appeal of the coverage denial within 180 days. Program provides RINVOQ at no charge to patients for up to 2 years or until they receive insurance coverage approval, whichever occurs earlier. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage.

†Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing healthcare professional (HCP). They are trained to direct patients to speak with their HCP about any treatment‑related questions, including further referrals.

Rinvoq Complete App

COMPLETE APP

Track treatment

The Complete App is designed to help patients stay on track with their prescribed RINVOQ or HUMIRA treatment by helping them:

  • Access additional resources, including a savings card for those that are eligible
  • Set customized medication reminders
  • Log symptoms
  • Log medication lot number and medication expiration date
Download on the App Store
Get it on Google Play
Rinvoq Complete

COMPLETEPRO.COM

Streamline the Rx process

CompletePro.com enables seamless enrollment into RINVOQ Complete and HUMIRA Complete, and helps streamline the prescription process for your patients.

With CompletePro.com, you can:

  • Request benefits verifications
  • Complete and submit prior authorizations
  • Send prescriptions to the patient’s specialty pharmacy of choice, with the option to include a savings card
  • Receive alerts for annual reauthorizations and renewals
  • Track and monitor where patients are in the prescription process

Learn more about streamlining the prescription process with Complete Pro:

Register now at

Downloadable Resources

Download RINVOQ resources to support your
patients and your practice.

RINVOQ SAFETY DATA

Review the safety profile of RINVOQ,
including both short- and long-term analyses

IMPORTANT SAFETY INFORMATION & INDICATIONS1

INDICATIONS1

RINVOQ is indicated for the treatment of:

  • Moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to one or more TNF blockers.
  • Active psoriatic arthritis in adults who have had an inadequate response or intolerance to one or more TNF blockers.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants, such as azathioprine and cyclosporine, is not recommended.

SERIOUS INFECTIONS

  • Active tuberculosis (TB), which may present with pulmonary or extrapulmonary disease. Test patients for latent TB before RINVOQ use and during therapy. Consider treatment for latent TB infection prior to RINVOQ use.
  • Invasive fungal infections, including cryptococcosis and pneumocystosis.
  • Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens.

MORTALITY

MALIGNANCIES

MAJOR ADVERSE CARDIOVASCULAR EVENTS

THROMBOSIS

HYPERSENSITIVITY

GASTROINTESTINAL PERFORATIONS

LABORATORY ABNORMALITIES

EMBRYO-FETAL TOXICITY

VACCINATION

LACTATION

HEPATIC IMPAIRMENT

ADVERSE REACTIONS

REFERENCES

  1. RINVOQ [package insert]. North Chicago, IL: AbbVie Inc.
  2. Data on File, AbbVie Inc. Payer reported lives. December 2021.

INDICATIONS & LIMITATION OF USE1

RINVOQ is indicated for the treatment of:

  • Moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to one or more
    TNF blockers.
  • Active psoriatic arthritis in adults who have had an inadequate response or intolerance to one or more TNF blockers.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCIES, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCIES, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

INDICATIONS & LIMITATION OF USE1

RINVOQ is indicated for the treatment of:

  • Moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to one or more
    TNF blockers.
  • Active psoriatic arthritis in adults who have had an inadequate response or intolerance to one or more TNF blockers.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCIES, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCIES, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION & INDICATIONS1

INDICATIONS1

RINVOQ is indicated for the treatment of:

  • Moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to one or more TNF blockers.
  • Active psoriatic arthritis in adults who have had an inadequate response or intolerance to one or more TNF blockers.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants, such as azathioprine and cyclosporine, is not recommended.

SERIOUS INFECTIONS

  • Active tuberculosis (TB), which may present with pulmonary or extrapulmonary disease. Test patients for latent TB before RINVOQ use and during therapy. Consider treatment for latent TB infection prior to RINVOQ use.
  • Invasive fungal infections, including cryptococcosis and pneumocystosis.
  • Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens.

MORTALITY

MALIGNANCIES

MAJOR ADVERSE CARDIOVASCULAR EVENTS

THROMBOSIS

HYPERSENSITIVITY

GASTROINTESTINAL PERFORATIONS

LABORATORY ABNORMALITIES

EMBRYO-FETAL TOXICITY

VACCINATION

LACTATION

HEPATIC IMPAIRMENT

ADVERSE REACTIONS